Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]

Affiliations

• ¹ Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
• ² Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
• ³ Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea.
• ⁴ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Surgery, Korea University Guro Hospital, Seoul, Korea.
• ⁶ Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
• ⁷ Department of Medicine, Graduate School, Kyung Hee University, Seoul, Korea.
• ⁸ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
• ¹⁰ Department of Biomedical Sciences, Dong-A University, Busan, Korea.
• ¹¹ Department of Health Sciences, The Graduate School of Dong-A University, Busan, Korea.
• ¹² Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.